๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cerebral ventricular enlargement and neuroleptic response in chronic schizophrenia: Preliminary findings with risperidone

โœ Scribed by Dr. Giuseppe Bersani; Piero Venturi; Giuseppe Tanfani; Paolo Pancheri


Book ID
102860449
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
506 KB
Volume
10
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis


In this pilot clinical study the aim was to investigate whether the clinical response to a chronic treatment with risperidone was related to brain morphology. We evaluated the relationship between Ventricular-Brain Ratio (VBR), and clinical response to risperidone, as assessed through the Positive and Negative Syndrome Scale (PANSS). Eighteen chronic schizophrenics (DSM 111-R diagnostic criteria) were subjected to a computerized tomographic scan. For the total PANSS and each PANSS subscale (Positive, Negative and General Psychopathology) the percentage change between baseline rating and the score measured at 28, 56 days and 1 year of treatment was calculated.

VBR was positively related to the percentage decrement of the total PANSS score, the Negative subscale score and the General Psychopathology subscale score as measured at one year of continuous treatment with risperidone. There was no significant differences between completers (subjects who complete the therapy with risperidone) ( N = 8) and noncompleters ( N = 10) when baseline clinical characteristcs were compared. VBR was not significantly different in the two subgroups.


๐Ÿ“œ SIMILAR VOLUMES


Combined serotonin-5-HT2 and dopamine-D2
โœ G. Bersani; G. M. Bressa; G. Meco; S. Marini; F. Pozzi ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 580 KB

Previous studies suggested a therapeutic action of the selective serotonin 5-HT2-antagonist ritanserin on negative symptoms of schizophrenia and on neuroleptic-induced parkinsonism. In this open trial the effect of risperidone, a combined serotonin-5-HT2-and dopamine-D,-antagonist, was studied on a